Genetron: Up on deal for liver cancer test in China

Genetron Holdings

06/01/2021 15:20

** U.S.-listed shares of Chinese medtech firm Genetron
Holdings  GTH.O  up 15% at $15.8 
    ** Co announces exclusive strategic partnership with Sino
Biopharma  1177.HK  subsidiary for its blood-based screening
test, HCCscreen, used for early detection of liver cancer in
China  urn:newsml:reuters.com:*:nBwb6Nr2Ra
    ** Under agreement, cos will work together to co-market and
co-promote HCCscreen in hospital market
    ** Genetron will pay Sino's unit a promotional fee based on
a pct of revenue generated from collaboration
    ** Exclusivity period is expected to last three years - Co
    ** Stock has fallen 1.2% in last 12 months

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))